Deep Cyclic Inhibition of MEK: A Transformational Approach to Durable & Safe Combinations in RAS-Mutant Cancers
- Chronic MEK inhibition is constrained by resistance and toxicity
- Atebimetinib (IMM-1-104) applies DCI, a distinct and translatable paradigm
- Broadens the therapeutic window and enables durable RAS-mutant cancer therapy